Modified FOLFIRINOX as a second-line therapy following gemcitabine plus nab-paclitaxel therapy in metastatic pancreatic cancer

Modified FOLFIRINOX as a second-line therapy following gemcitabine plus nab-paclitaxel therapy in metastatic pancreatic cancer

Abstract Background There is no established second-line treatment after failure of gemcitabine plus nab-paclitaxel (GnP) therapy for metastatic pancreatic cancer (MPC). The purpose of this study was to evaluate the efficacy and tolerability of the modified FOLFIRINOX (mFFX) as a second-line therapy...

Full description

Bibliographic Details
Main Authors: Masashi Sawada, Akiyoshi Kasuga, Takafumi Mie, Takaaki Furukawa, Takanobu Taniguchi, Koshiro Fukuda, Yuto Yamada, Tsuyoshi Takeda, Ryo Kanata, Masato Matsuyama, Takashi Sasaki, Masato Ozaka, Naoki Sasahira
Format: Article
Language:English
Published: BMC 2020-05-01
Series:BMC Cancer
Subjects:
Pancreatic cancer
Second-line chemotherapy
Modified FOLFIRINOX
Gemcitabine
Nab-paclitaxel
Prognostic factor
Online Access:http://link.springer.com/article/10.1186/s12885-020-06945-8

Internet

http://link.springer.com/article/10.1186/s12885-020-06945-8

Similar Items